Immune Sensitive Tumor clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
open to eligible people ages 18 years and up
This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE[s]); and the dose expansion stage is to evaluate the preliminary antitumor activity of XB628 as a single agent and in combination with zanzalintinib.
at UCSF
Our lead scientists for Immune Sensitive Tumor research studies include Kelly Fitzgerald.
Last updated: